cilostazol has been researched along with Cardiac Diseases in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol is a potent type III phosphodiesterase inhibitor with pharmacological effects that include vasodilatation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth." | 2.44 | Cilostazol in the management of vascular disease. ( Dalainas, I, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z | 1 |
| Qian, J | 1 |
| Chen, Y | 1 |
| Ma, J | 1 |
| Ge, J | 1 |
| Dalainas, I | 1 |
2 reviews available for cilostazol and Cardiac Diseases
| Article | Year |
|---|---|
Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: a meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Dise | 2013 |
Cilostazol in the management of vascular disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; | 2007 |
1 trial available for cilostazol and Cardiac Diseases
| Article | Year |
|---|---|
Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: a meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Dise | 2013 |